Naperville, IL -- (SBWire) -- 08/22/2014 --Reportstack, provider of premium market research reports announces the addition of Global Multiple Sclerosis Drugs Market 2014-2018 market report to its offering

About Multiple Sclerosis and Disease Types
Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems. Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.

Analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.

Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
Americas
APAC
EMEA

Key Vendors
Bayer
Biogen Idec
Merck Serono
Novartis
Teva Pharmaceutical

Other Prominent Vendors
AB Science
Abbvie
Acorda
Active Biotech
GlaxoSmithKline
Glenmark
Mitsubishi Tanabe
Opexa
Pfizer
Sanofi

Market Driver
Unmet Medical Needs
For a full, detailed list, view our report

Market Challenge
Unknown Etiology of the Disease
For a full, detailed list, view our report

Market Trend
Introduction of Disease-modifying Drugs
For a full, detailed list, view our report

Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Companies Mentioned
Americas , APAC, EMEA

Key Vendors, Bayer, Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical, AB Science, Abbvie, Acorda, Active Biotech, GlaxoSmithKline, Glenmark, Mitsubishi Tanabe, Opexa, Pfizer, Sanofi

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/167723/global-multiple-sclerosis-drugs-market-2014-2018-.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604